DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Bushnell DL. et al.
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.
EJNMMI Res 2014;
4: 38
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.